LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Stock List・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Closed

13.17 0.38

Buy Sell

Overview

Share price change

24h

Current

Min

12.93

Max

13.33

Key metrics
By Trading Economics
Income	-6.4M -20M
Sales	-807K 71M
EPS	-0.13
Profit margin	-28.24
Employees	624
EBITDA	-7.9M -14M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+47.91% upside

Dividends
By Dow Jones
Next Earnings	4 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-150M 2.2B
Previous open	12.79
Previous close	13.17

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

8.81 / 10.18 Support & Resistance

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 May 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 May 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 May 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 May 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 May 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 May 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 May 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 May 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 May 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 May 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 May 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 May 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 May 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 May 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 May 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 May 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

47.91% upside

12 Months Forecast

Average 19.42 USD 47.91%

High 22 USD

Low 13.54 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Adaptive Biotechnologies Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.